What does this research mean for the field?

First-line treatment with azacitidine plus venetoclax yields high complete response rates and favorable overall survival in younger, intensive chemotherapy-eligible AML patients who have a low likelihood of benefiting from standard intensive chemotherapy. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

To assess real-world outcomes of first-line venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients who are chemotherapy-ineligible or chemotherapy-eligible with poor expected response to induction.

September 5, 2026Clinical and Experimental MedicineOpen Access

Real-world evidence on the use of lower-intensity treatment with venetoclax and azacitidine in newly diagnosed AML in younger patients

View Full Paper

Ask AI

Bookmark

Authors

MPMarta Isabel Pereira BMBárbara Marques SMSandra Marini

Discussion

Member takes

Overview

Cohort study reveals favorable survival with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia, indicating lower-intensity therapy benefits younger high-risk patients.

Key Points

To assess real-world outcomes of first-line venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients who are chemotherapy-ineligible or chemotherapy-eligible with poor expected response to induction.
Conducted a real-world cohort study of N=53 newly diagnosed AML patients (median age 65.8 years; 75.5% adverse risk) receiving first-line venetoclax plus azacitidine.
Tracked treatment response, measurable residual disease (MRD), and overall survival (OS) over a median follow-up of 17.3 months.
Bone marrow complete remission rates in hematologic responders exceeded 90% overall and reached 100% in intensive chemotherapy-eligible patients, with MRD negativity in over 90% of complete responders.
Median overall survival was 19.4 months, with an estimated 3-year survival rate of 65.9% (median not reached) in patients aged 65–74 and 57.3% (median not reached) in intensive chemotherapy-eligible patients with non-favorable risk.

Cite This Study

Pereira et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4726b95aff0620ec34d https://doi.org/10.1007/s10238-026-02307-z

View Full Paper

Ask AI

Bookmark

September 5, 2026Clinical and Experimental MedicineOpen Access

Real-world evidence on the use of lower-intensity treatment with venetoclax and azacitidine in newly diagnosed AML in younger patients

View Full Paper

Ask AI

Bookmark

Authors

MPMarta Isabel Pereira BMBárbara Marques SMSandra Marini

Discussion

Member takes

Overview

Cohort study reveals favorable survival with venetoclax and azacitidine in newly diagnosed acute myeloid leukemia, indicating lower-intensity therapy benefits younger high-risk patients.

Key Points

To assess real-world outcomes of first-line venetoclax plus azacitidine in newly diagnosed acute myeloid leukemia patients who are chemotherapy-ineligible or chemotherapy-eligible with poor expected response to induction.
Conducted a real-world cohort study of N=53 newly diagnosed AML patients (median age 65.8 years; 75.5% adverse risk) receiving first-line venetoclax plus azacitidine.
Tracked treatment response, measurable residual disease (MRD), and overall survival (OS) over a median follow-up of 17.3 months.
Bone marrow complete remission rates in hematologic responders exceeded 90% overall and reached 100% in intensive chemotherapy-eligible patients, with MRD negativity in over 90% of complete responders.
Median overall survival was 19.4 months, with an estimated 3-year survival rate of 65.9% (median not reached) in patients aged 65–74 and 57.3% (median not reached) in intensive chemotherapy-eligible patients with non-favorable risk.

Cite This Study

Pereira et al. (2026) studied this question.

synapsesocial.com/papers/6a9bd4726b95aff0620ec34d https://doi.org/10.1007/s10238-026-02307-z

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark